Dr. Xingwang Xie founded CorreGene in 2016 and served as board chairman and CEO since 2019.

Dr. Xie is a member of the Multidisciplinary Tumor Diagnosis (MDD) collaboration group of the Tumor Marker Committee of the Chinese Anti-Cancer Association and a member of the Clinical Application Committee of pharmaceutical biotechnology of the China Medicinal Biotech Association (CMBA).

From 2009 to 2019, Dr. Xie started his career as a scientist at the Peking University People’s Hospital, Peking University Hepatology Institute, and has devoted over 10 years to studying the genomics and immunobiology of cancer and their clinical implications. During this period, Dr. Xie been responsible for several major research programs from the National Natural Science Foundation of China and the Beijing Natural Science Foundation. He was also the core members of several projects from National Science and Technology Major Project.

Dr. Xie have participated in many immunotherapy trails for the treatment of chronic hepatitis and liver cancer, including cell therapies, tumor associated antigen vaccines and tumor neoantigen vaccines. He has published more than 20 papers in peer-reviewed journals and is the inventor of more than 10 patents or computer software copyrights.

Dr. Xie received an MD. (bachelor's degree in clinical medicine) from Medical College of Wuhan University of science and technology in 2006, a master's degree in medicine from the Department of medicine of Peking University in 2009 and a Ph. D. in medicine from China CDC (Center for Disease Control and prevention) in 2018.

Dr. Xingwang Xie founded CorreGene in 2016 and served as board chairman and CEO since 2019.

Dr. Xie is a member of the Multidisciplinary Tumor Diagnosis (MDD) collaboration group of the Tumor Marker Committee of the Chinese Anti-Cancer Association and a member of the Clinical Application Committee of pharmaceutical biotechnology of the China Medicinal Biotech Association (CMBA).

From 2009 to 2019, Dr. Xie started his career as a scientist at the Peking University People’s Hospital, Peking University Hepatology Institute, and has devoted over 10 years to studying the genomics and immunobiology of cancer and their clinical implications. During this period, Dr. Xie been responsible for several major research programs from the National Natural Science Foundation of China and the Beijing Natural Science Foundation. He was also the core members of several projects from National Science and Technology Major Project.

Dr. Xie have participated in many immunotherapy trails for the treatment of chronic hepatitis and liver cancer, including cell therapies, tumor associated antigen vaccines and tumor neoantigen vaccines. He has published more than 20 papers in peer-reviewed journals and is the inventor of more than 10 patents or computer software copyrights.

Dr. Xie received an MD. (bachelor's degree in clinical medicine) from Medical College of Wuhan University of science and technology in 2006, a master's degree in medicine from the Department of medicine of Peking University in 2009 and a Ph. D. in medicine from China CDC (Center for Disease Control and prevention) in 2018.

Dr. Xingwang Xie founded CorreGene in 2016 and served as board chairman and CEO since 2019.

Dr. Xie is a member of the Multidisciplinary Tumor Diagnosis (MDD) collaboration group of the Tumor Marker Committee of the Chinese Anti-Cancer Association and a member of the Clinical Application Committee of pharmaceutical biotechnology of the China Medicinal Biotech Association (CMBA).

From 2009 to 2019, Dr. Xie started his career as a scientist at the Peking University People’s Hospital, Peking University Hepatology Institute, and has devoted over 10 years to studying the genomics and immunobiology of cancer and their clinical implications. During this period, Dr. Xie been responsible for several major research programs from the National Natural Science Foundation of China and the Beijing Natural Science Foundation. He was also the core members of several projects from National Science and Technology Major Project.

Dr. Xie have participated in many immunotherapy trails for the treatment of chronic hepatitis and liver cancer, including cell therapies, tumor associated antigen vaccines and tumor neoantigen vaccines. He has published more than 20 papers in peer-reviewed journals and is the inventor of more than 10 patents or computer software copyrights.

Dr. Xie received an MD. (bachelor's degree in clinical medicine) from Medical College of Wuhan University of science and technology in 2006, a master's degree in medicine from the Department of medicine of Peking University in 2009 and a Ph. D. in medicine from China CDC (Center for Disease Control and prevention) in 2018.

Dr. Xingwang Xie founded CorreGene in 2016 and served as board chairman and CEO since 2019.

Dr. Xie is a member of the Multidisciplinary Tumor Diagnosis (MDD) collaboration group of the Tumor Marker Committee of the Chinese Anti-Cancer Association and a member of the Clinical Application Committee of pharmaceutical biotechnology of the China Medicinal Biotech Association (CMBA).

From 2009 to 2019, Dr. Xie started his career as a scientist at the Peking University People’s Hospital, Peking University Hepatology Institute, and has devoted over 10 years to studying the genomics and immunobiology of cancer and their clinical implications. During this period, Dr. Xie been responsible for several major research programs from the National Natural Science Foundation of China and the Beijing Natural Science Foundation. He was also the core members of several projects from National Science and Technology Major Project.

Dr. Xie have participated in many immunotherapy trails for the treatment of chronic hepatitis and liver cancer, including cell therapies, tumor associated antigen vaccines and tumor neoantigen vaccines. He has published more than 20 papers in peer-reviewed journals and is the inventor of more than 10 patents or computer software copyrights.

Dr. Xie received an MD. (bachelor's degree in clinical medicine) from Medical College of Wuhan University of science and technology in 2006, a master's degree in medicine from the Department of medicine of Peking University in 2009 and a Ph. D. in medicine from China CDC (Center for Disease Control and prevention) in 2018.

Dr. Xingwang Xie founded CorreGene in 2016 and served as board chairman and CEO since 2019.

Dr. Xie is a member of the Multidisciplinary Tumor Diagnosis (MDD) collaboration group of the Tumor Marker Committee of the Chinese Anti-Cancer Association and a member of the Clinical Application Committee of pharmaceutical biotechnology of the China Medicinal Biotech Association (CMBA).

From 2009 to 2019, Dr. Xie started his career as a scientist at the Peking University People’s Hospital, Peking University Hepatology Institute, and has devoted over 10 years to studying the genomics and immunobiology of cancer and their clinical implications. During this period, Dr. Xie been responsible for several major research programs from the National Natural Science Foundation of China and the Beijing Natural Science Foundation. He was also the core members of several projects from National Science and Technology Major Project.

Dr. Xie have participated in many immunotherapy trails for the treatment of chronic hepatitis and liver cancer, including cell therapies, tumor associated antigen vaccines and tumor neoantigen vaccines. He has published more than 20 papers in peer-reviewed journals and is the inventor of more than 10 patents or computer software copyrights.

Dr. Xie received an MD. (bachelor's degree in clinical medicine) from Medical College of Wuhan University of science and technology in 2006, a master's degree in medicine from the Department of medicine of Peking University in 2009 and a Ph. D. in medicine from China CDC (Center for Disease Control and prevention) in 2018.

Dr. Xingwang Xie founded CorreGene in 2016 and served as board chairman and CEO since 2019.

Dr. Xie is a member of the Multidisciplinary Tumor Diagnosis (MDD) collaboration group of the Tumor Marker Committee of the Chinese Anti-Cancer Association and a member of the Clinical Application Committee of pharmaceutical biotechnology of the China Medicinal Biotech Association (CMBA).

From 2009 to 2019, Dr. Xie started his career as a scientist at the Peking University People’s Hospital, Peking University Hepatology Institute, and has devoted over 10 years to studying the genomics and immunobiology of cancer and their clinical implications. During this period, Dr. Xie been responsible for several major research programs from the National Natural Science Foundation of China and the Beijing Natural Science Foundation. He was also the core members of several projects from National Science and Technology Major Project.

Dr. Xie have participated in many immunotherapy trails for the treatment of chronic hepatitis and liver cancer, including cell therapies, tumor associated antigen vaccines and tumor neoantigen vaccines. He has published more than 20 papers in peer-reviewed journals and is the inventor of more than 10 patents or computer software copyrights.

Dr. Xie received an MD. (bachelor's degree in clinical medicine) from Medical College of Wuhan University of science and technology in 2006, a master's degree in medicine from the Department of medicine of Peking University in 2009 and a Ph. D. in medicine from China CDC (Center for Disease Control and prevention) in 2018.